Evidence map›Paper›PMID 38814273›Full record

ArticleJournal of neurochemistry2024

Effect of blood collection tube containing protease inhibitors on the pre-analytical stability of Alzheimer's disease plasma biomarkers.

Yijun Chen, Xuemei Zeng, Jihui L Diaz, Anuradha Sehrawat, Tara K Lafferty, James J Boslett, William E Klunk, Tharick A Pascoal, Victor L Villemagne, Ann D Cohen and 3 more

Abstract read
In one paragraph

Article in Journal of neurochemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Physical activity, aerobic fitness, and AD blood biomarkers: The IGNITE study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Yijun ChenDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0009-0001-4579-4057
Xuemei ZengDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Jihui L DiazDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Anuradha SehrawatDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Tara K LaffertyDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
James J BoslettDepartment of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
William E KlunkDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Tharick A PascoalDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Victor L VillemagneDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-5832-9875
Ann D CohenDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Oscar I LopezDepartment of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Nathan A YatesDepartment of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Thomas K KarikariDepartment of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-1422-4358

Funding

Vascular Moderators of the Impact of Alzheimer's Pathology in the Young-OldP01AG025204 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HOWARD J AIZENSTEIN, Ann D. Cohen · 2005 to 2026
$56.5M
Longitudinal multicenter head-to-head harmonization of tau PET tracersR01AG073267 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAKER, SUZANNE L, PASCOAL, THARICK · 2021 to 2025
$41.1M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
Investigating Gains in Neurocognition in an Intervention Trial of Exercise SupplementR01AG053952 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BURNS, JEFFREY MURRAY, ERICKSON, KIRK I · 2016 to 2020
$27.5M
Mild Cognitive Impairment: A Prospective Community StudyR37AG023651 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Carmen Andreescu, MARY GANGULI · 2021 to 2026
$18.2M
Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in bloodR01AG083874 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas K Karikari · 2023 to 2026
$14.5M
The RAW Brain - The Effect of Rumination, Anxiety and Worry on Aging and Dementia RiskR01MH108509 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Carmen Andreescu · 2016 to 2026
$10.6M
Predictors of Altered CNS Structure, Function, and Connectomics in the Elderly using a Health Disparities FrameworkR01AG072641 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ann D. Cohen · 2022 to 2026
$9.6M
Subclinical vascular disease and AD pathology in the transition from midlife to old ageRF1AG052525 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOPEZ, OSCAR L., REIS, STEVEN E · 2018 to 2018
$9.3M
Roles of Gray Matter Brain Aging and Small Vessel Disease in AD PathophysiologyRF1AG025516 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AIZENSTEIN, HOWARD J, VILLEMAGNE, VICTOR LUIS · 2014 to 2021
$9.0M
Alzheimer Diagnosis in older Adults with Chronic Conditions ADACC NetworkU24AG082930 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Nicole R. Fowler, Thomas K Karikari · 2023 to 2026
$7.3M
Recurrence markers, cognitive burden and neurobiological homeostasis in latelife depression (REMBRANDT) - SupplementR01MH121619 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANDREESCU, CARMEN · 2020 to 2024
$5.1M
Joseph A. Massaro Alzheimer's Research Fund of The Pittsburgh Foundation AD2018-97918NIA NIH HHS P01 AG025204NIA NIH HHS P30 AG066468NIA NIH HHS R01 AG025516NIA NIH HHS R01 AG053952NIA NIH HHS R01 AG072641NIA NIH HHS R01 AG073267NIA NIH HHS R01 AG075336NIA NIH HHS R01 AG083874NIA NIH HHS R37 AG023651NIA NIH HHS RF1 AG025516NIA NIH HHS RF1 AG052525NIA NIH HHS U24 AG082930NIH HHS P01 AG025204NIH HHS P30 AG066468NIH HHS R01 AG053952NIH HHS R01 AG072641NIH HHS R01 AG073267NIH HHS R01 AG075336NIH HHS R01 AG083874NIH HHS R01 MH108509NIH HHS R01 MH121619NIH HHS R37 AG023651NIH HHS RF1 AG025516NIH HHS RF1 AG052525NIH HHS U24 AG082930NIMH NIH HHS R01 MH108509NIMH NIH HHS R01 MH121619
6 · The paper itself

Abstract

The reliability of plasma biomarkers of Alzheimer's disease (AD) can be compromised by protease-induced degradation. This can limit the feasibility of conducting plasma biomarker studies in environments that lack the capacity for immediate processing and appropriate storage of blood samples. We hypothesized that blood collection tube supplementation with protease inhibitors can improve the stability of plasma biomarkers at room temperatures (RT). In this study, we conducted a comparative analysis of blood biomarker stability in traditional ethylenediaminetetraacetic acid (EDTA) tubes versus BD™ P100 collection tubes, the latter being coated with a protease inhibitor cocktail. The stability of six plasma AD biomarkers was evaluated over time under RT conditions. We evaluated three experimental approaches. In Approach 1, pooled plasma samples underwent storage at RT for up to 96 h. In Approach 2, plasma samples isolated upfront from whole blood collected into EDTA or P100 tubes were stored at RT for 0 h or 24 h before biomarker measurements. In Approach 3, whole blood samples were collected into paired EDTA and P100 tubes, followed by storage at RT for 0 h or 24 h before isolating the plasma for analyses. Biomarkers were measured with Single Molecule Array (Simoa) and immunoprecipitation-mass spectrometry (IP-MS) assays. Both the IP-MS and Simoa methods revealed that the use of P100 tubes significantly improves the stability of Aβ42 and Aβ40 across all approaches. However, the Aβ42/Aβ40 ratio levels were significantly stabilized only in the IP-MS assay in Approach 3. No significant differences were observed in the levels of plasma p-tau181, GFAP, and NfL for samples collected using either tube type in any of the approaches. Supplementation of blood collection tubes with protease inhibitors could reduce the protease-induced degradation of plasma Aβ42 and Aβ40, and the Aβ42/40 ratio for the IP-MS assay. These findings have crucial implications for preanalytical procedures, particularly in resource-limited settings.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersBlood Specimen CollectionProtease InhibitorsAgedAged, 80 and overEdetic AcidFemaleHumansMalePeptide Fragmentstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-40)BiomarkersEdetic AcidPeptide FragmentsProtease Inhibitorstau ProteinsAlzheimer's disease and related disordersblood biomarkersdelayed centrifugationpreanalytical handlingprotease inhibitionproteolytic processing

Identifiers

PMID38814273
PMCPMC11449657

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.